Skip to main content

Advertisement

SpringerLink
Log in

Bisphosphonate Actions on Cancer

  • Review
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Bisphosphonates (BPs) suppress cancer cell colonization in bone associated with cancers such as breast cancer and multiple myeloma. The mechanism of the suppressive action of BPs is thought to be due to an inhibition of osteoclastic bone resorption which releases bone-stored growth factors that feed cancer cells colonizing bone. Recently, data are accumulating that BP suppresses growth and induces apoptosis in cancer cells in culture, suggesting that BP directly influences survival of cancer cells in an osteoclast-independent manner. These results raise the possibility that BP inhibits cancer growth in organs other than bone. However, evidence is limited that BP reduces tumor growth in non-bone sites in cancer patients. In this review, we discuss the effectiveness of BP on breast cancer colonization in non-bone sites and our results in animal models with metastases. With currently available clinical and in vivo experimental data, BPs are definitely beneficial for the treatment of cancer patients who manifest clinically detectable bone metastases. However, it is not recommended that BP be given as a preventative to patients with visceral metastases and of no evidence of bone metastases. Whether individual BP with different chemical structure has unique biological or biochemical action is an intriguing question but open at the moment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. G Van der Pluijm H Vloedgraven E van Beek L van der Wee-Pals C Lowik S Papapoulos (1996) ArticleTitleBisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98 698–705 Occurrence Handle1:CAS:528:DyaK28XkvVeisrg%3D Occurrence Handle8698861

    CAS  PubMed  Google Scholar 

  2. S Boisser S Magnetto L Frappart B Cuzin FH Ebetino PD Delmas P Clezardin (1997) ArticleTitleBisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57 3890–3894 Occurrence Handle9307266

    PubMed  Google Scholar 

  3. S Boissier M Ferreras O Peyruchaud S Magnetto FH Ebetino M Colombel P Delmas JM Delaisse P Clezardin (2000) ArticleTitleBisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 2949–2954 Occurrence Handle1:CAS:528:DC%2BD3cXjvFOltrY%3D Occurrence Handle10850442

    CAS  PubMed  Google Scholar 

  4. CM Shipman PI Croucher RGG Russell MH Helfrich MJ Rogers (1999) ArticleTitleThe bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58 5294–5297

    Google Scholar 

  5. O Fromigue L Lagneaux JJ Body (2000) ArticleTitleBisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 45 2211–2221

    Google Scholar 

  6. MV Lee EM Fong FR Singer RS Guenette (2001) ArticleTitleBisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61 2602–2608 Occurrence Handle1:CAS:528:DC%2BD3MXisVSks7g%3D Occurrence Handle11289137

    CAS  PubMed  Google Scholar 

  7. IJ Diet E-F Solomayer SD Costa C Gollan R Goerner D Wallwiener M Kaufmann G Bastert (1998) ArticleTitleReduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 357–363

    Google Scholar 

  8. T Saarto C Blomqvist P Virkkunen II Elomaa (2001) ArticleTitleAdjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19 10–17 Occurrence Handle1:CAS:528:DC%2BD3MXot1Whuw%3D%3D Occurrence Handle11134190

    CAS  PubMed  Google Scholar 

  9. T Powles S Paterson JA Kanis et al. (2002) ArticleTitleRandomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20 3219–3224 Occurrence Handle10.1200/JCO.2002.11.080 Occurrence Handle1:CAS:528:DC%2BD38XmsF2rsrs%3D Occurrence Handle12149294

    Article  CAS  PubMed  Google Scholar 

  10. RE Coleman RD Rubens (1987) ArticleTitleThe clinical course of bone metastases from breast cancer. Br J Cancer 55 61–66 Occurrence Handle1:STN:280:BiiC38fnsFw%3D Occurrence Handle3814476

    CAS  PubMed  Google Scholar 

  11. H Fleisch A Reszka G Rodan M Rogers JP Bilezikian LG Raisz GA Rodan (2001) Mechanism of action. Principles of bone biology. Academic Press San Diego 1361–1385

    Google Scholar 

  12. MJ Rogers S Gordon HL Benford FP Coxon SP Luckman J Monkkonen JC Frith (2000) ArticleTitleCellular and molecular mechanism of action of bisphosphonates. Cancer 88 2961–2978 Occurrence Handle10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C Occurrence Handle1:CAS:528:DC%2BD3cXksVCmsLw%3D Occurrence Handle10898340

    Article  CAS  PubMed  Google Scholar 

  13. GN Hortobagyi RL Theriault L Porter D Blayney A Lipton C Sinoff H Wheeler JF Simeone J Seaman RD Knight (1996) ArticleTitleEfficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335 1785–1791

    Google Scholar 

  14. JJ Body R Bartl P Burckhardt et al. (1998) ArticleTitleCurrent use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16 3890–3899 Occurrence Handle1:CAS:528:DyaK1MXovFCl Occurrence Handle9850035

    CAS  PubMed  Google Scholar 

  15. GR Mundy T Yoneda (1998) ArticleTitleBisphosphonates as anticancer drugs. N Engl J Med 339 398–400 Occurrence Handle10.1056/NEJM199808063390609 Occurrence Handle1:STN:280:DyaK1czks1yhtw%3D%3D Occurrence Handle9691109

    Article  CAS  PubMed  Google Scholar 

  16. JR Berenson BE Hillner RA Kyle K Anderson A Lipton GC Yee JS Biermann (2002) ArticleTitleAmerican Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 3719–3736 Occurrence Handle10.1200/JCO.2002.06.037 Occurrence Handle12202673

    Article  PubMed  Google Scholar 

  17. A Sasaki BF Boyce B Story KR Wright M Chapman R Boyce GR Mundy T Yoneda (1995) ArticleTitleBisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55 3551–3557 Occurrence Handle1:CAS:528:DyaK2MXnsFGhsrw%3D Occurrence Handle7627963

    CAS  PubMed  Google Scholar 

  18. DE Hughes KR Wright HL Uy A Sasaki T Yoneda GD Roodman GR Mundy BF Boyce (1995) ArticleTitleBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 1478–1487 Occurrence Handle1:CAS:528:DyaK2MXpsFGmsbo%3D Occurrence Handle8686503

    CAS  PubMed  Google Scholar 

  19. T Hiraga PJ Williams GR Mundy T Yoneda (2201) ArticleTitleThe bisphosphonate ibandronate promotes apoptosis in MDA-231 human breast cancer cells in bone metastases. Cancer Res 61 4418–4424

    Google Scholar 

  20. M Sato W Grasser N Endo R Akins H Simmons DD Thompson E Golub GA Rodan (1991) ArticleTitleBisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 2095–2105 Occurrence Handle1:CAS:528:DyaK38XjsVGgtA%3D%3D Occurrence Handle1661297

    CAS  PubMed  Google Scholar 

  21. Diel IJ, Solomayer E-F, Gollan C, Shutz F, Bastert G (2000) Bisphosphonates in the reduction of metastases in breast cancer: results of the extended follow-up of the first study population (abstract 314). Proceedings ASCO

    Google Scholar 

  22. PJ Kostenuik FW Orr K Suyama FW Orr (1993) ArticleTitleIncreased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 53 5452–5457

    Google Scholar 

  23. ME Stearns M Wang (1996) ArticleTitleEffects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metastasis 16 116–131 Occurrence Handle1:CAS:528:DyaK2sXktV2js78%3D Occurrence Handle9186547

    CAS  PubMed  Google Scholar 

  24. T Michigami T Hiraga PJ Williams R Nishimura GR Mundy T Yoneda (2002) ArticleTitleThe effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75 249–258 Occurrence Handle10.1023/A:1019905111666 Occurrence Handle1:CAS:528:DC%2BD38XmsFWmtb8%3D Occurrence Handle12353814

    Article  CAS  PubMed  Google Scholar 

  25. T Yoneda T Michigami B Yi PJ Williams M Niewolna T Hiraga (2000) ArticleTitleAction of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88 2979–2988 Occurrence Handle10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.3.CO;2-L Occurrence Handle1:CAS:528:DC%2BD3cXksVCmsL0%3D Occurrence Handle10898341

    Article  CAS  PubMed  Google Scholar 

  26. BE Hillner JN Ingle JR Berenson NA Janjan KS Albain A Lipton G Yee JS Biermann RT Chlebowski DG Pfister (2000) ArticleTitleAmerican society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18 1378–1391 Occurrence Handle1:STN:280:DC%2BD3c7otF2jtg%3D%3D Occurrence Handle10715310

    CAS  PubMed  Google Scholar 

  27. K Sawada K Morishige M Tahara R Kawagishi Y Ikebuchi K Tasaka Y Murata (2002) ArticleTitleAlendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 62 6015–6020 Occurrence Handle1:CAS:528:DC%2BD38XosF2nu70%3D Occurrence Handle12414621

    CAS  PubMed  Google Scholar 

  28. JR Green K Muller KA Jaeggi (1994) ArticleTitlePreclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9 745–751 Occurrence Handle1:CAS:528:DyaK2cXlt1Gitro%3D Occurrence Handle8053405

    CAS  PubMed  Google Scholar 

  29. P Fournier S Boissier S Filleur J Guglielmi F Cabon M Colombel P Clezardin (2002) ArticleTitleBisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 6538–6544 Occurrence Handle1:CAS:528:DC%2BD38XovFOksrk%3D Occurrence Handle12438248

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Department of Medicine, Osaka University Graduate School of Dentistry, Japan and Endocrine Research, The University of Texas Health Science Center at San Antonio, Texas, USA

    T. Yoneda, N. Hashimoto & T. Hiraga

Authors
  1. T. Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Hiraga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Yoneda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoneda, T., Hashimoto, N. & Hiraga, T. Bisphosphonate Actions on Cancer . Calcif Tissue Int 73, 315–318 (2003). https://doi.org/10.1007/s00223-002-0025-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-002-0025-x

Keywords

Search

Navigation